Acadian Asset Management’s RAPT Therapeutics RAPT Stock Holding History

Acadian Asset Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,788	Closed	-$568K	–	2215
2025 Q4	$568K	Hold	16,788	–	–	﹤0.01%	1269
2025 Q3	$432K	Sell	16,788 -74,287	-82%	-$972K	﹤0.01%	1259
2025 Q2	$726K	Buy	91,075 +9,905	+12%	+$75.6K	﹤0.01%	1060
2025 Q1	$790K	Sell	81,170 -26,691	-25%	-$262K	﹤0.01%	985
2024 Q4	$1.36M	Buy	107,861 +2,591	+2%	+$32.9K	﹤0.01%	865
2024 Q3	$1.69M	Buy	105,270 +46,872	+80%	+$948K	0.01%	791
2024 Q2	$1.42M	Buy	58,398 +57,035	+4,185%	+$2.63M	﹤0.01%	882
2024 Q1	$97K	Buy	+1,363	New	+$190K	﹤0.01%	1293

Acadian Asset Management's RAPT Position: Q1 2026 in Review

Acadian Asset Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 16,788 shares — an estimated $568K sold.

Acadian Asset Management first reported a position in RAPT in Q1 2024 and held it in 8 quarters. The position peaked at $1.69M in Q3 2024. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Acadian Asset Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Acadian Asset Management sold 16,788 RAPT Therapeutics shares in Q1 2026, an estimated $568K.
Acadian Asset Management first reported a position in RAPT Therapeutics in Q1 2024 and held it in 8 quarters.
Acadian Asset Management's RAPT Therapeutics position peaked at $1.69M in Q3 2024.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.